Conflict of interest statement: The trial was sponsored by GlaxoSmithKline 
Biologicals SA (GSK), the vaccine developer and manufacturer, and funded by both 
GSK Biologicals SA and the PATH Malaria Vaccine Initiative (MVI). All centers 
declare receiving a grant from MVI for running the trial. Author travel and 
accommodation related to this trial were financed by MVI. GlaxoSmithKline 
Biologicals SA received a grant from MVI to run the trial. MVI received a grant 
from the Bill & Melinda Gates Foundation to run this trial and to compensate MVI 
authors for trial-related travel. Additional conflicts of interest are as 
follows: JJA and PAl declare that their institutions received grant from the 
Catalan government and from the International Agency for Development and 
Cooperation. NA, CO, and KO declare that their institutions received a grant 
from the Malaria Clinical Trial Alliance. PB, SD, BG, CK, PL, CMai, GMwam, BO, 
and LO declare that their institution has received grants from MVI for other 
malaria studies. KM declares that his institution received a grant from the 
Wellcome Trust and that he received support from USAID and the Bill & Melinda 
Gates Foundation to participate in a scientific advisory group on malaria. MML 
declares that she received non-financial support from the WHO and the Biomérieux 
Foundation. PN declares that she received financial support from GSK to present 
the results of the study at ASTMH congress in 2012. LO declares that he received 
support from GSK to carry out clinical and epidemiological studies. JSa has 
received (for the Center) some GlaxoSmithKline group of companies' consultancy 
fees for other studies. MTa is a board member of the Optimus Foundation, and his 
institution is reimbursed for his activities on the scientific advisory board of 
the Novartis Institute for Tropical Diseases. He also has received for his 
institution other grants from MVI and from the Bill & Melinda Gates Foundation, 
and travel reimbursements from MVI and Sanaria corp. All GSK Vaccines authors 
are, or were at the time of the study, employed by the GlaxoSmithKline group of 
companies. JC now works as an independent consultant for GSK Vaccines. WRB, JC, 
EJ, DLa, OOA, JV, AL, and MLi have shares/stock options in the GlaxoSmithKline 
group of companies. JC and WRB declare that they are named inventors on patents 
for which the rights have been assigned to GlaxoSmithKline group of companies. 
DK, DLe, and BS are employees at PATH-MVI. DSc is employed by the London School 
of Hygiene & Tropical Medicine, and his consultancy activities for MVI are 
funded as a grant to the LSHTM by MVI. DK holds stock or stock options from 
Merck, Sharpe & Dome.